Active Filter(s):
Details:
The Series A will support Faze’s preclinical research in two initial therapeutic focus areas – ALS and myotonic dystrophy type 1 (DM1) – as well as research to explore condensate biology in other disease areas.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Third Rock Ventures
Deal Size: $81.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 10, 2020